Metastatic Pancreatic Cancer - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 416 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Metastatic Pancreatic Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Metastatic Pancreatic Cancer - Pipeline Review, H2 2016', provides an overview of the Metastatic Pancreatic Cancer pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Metastatic Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Pancreatic Cancer and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
- The report reviews pipeline therapeutics for Metastatic Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Metastatic Pancreatic Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Metastatic Pancreatic Cancer

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Pancreatic Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Metastatic Pancreatic Cancer - Overview 11
Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis 12
Metastatic Pancreatic Cancer - Therapeutics under Development by Companies 13
Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 17
Metastatic Pancreatic Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Metastatic Pancreatic Cancer - Products under Development by Companies 21
Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes 26
Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development 27
AbbVie Inc 27
Aduro BioTech, Inc. 28
ArQule, Inc. 29
Array BioPharma Inc. 30
AstraZeneca Plc 31
Axcentua Pharmaceuticals AB 32
Berg LLC 33
BioLineRx, Ltd. 34
Bionomics Limited 35
Boehringer Ingelheim GmbH 36
Boston Biomedical, Inc. 37
Bristol-Myers Squibb Company 38
Celgene Corporation 39
Clovis Oncology, Inc. 40
Cornerstone Pharmaceuticals, Inc. 41
CrystalGenomics, Inc. 42
CTI BioPharma Corp. 43
CytRx Corporation 44
Daiichi Sankyo Company, Limited 45
Eleison Pharmaceuticals LLC 46
Eli Lilly and Company 47
Ensol Biosciences Inc. 48
Erytech Pharma SA 49
F. Hoffmann-La Roche Ltd. 50
Fountain Biopharma Inc. 51
Gilead Sciences, Inc. 52
GlaxoSmithKline Plc 53
Immodulon Therapeutics Ltd. 54
Incyte Corporation 55
MabVax Therapeutics Holdings, Inc. 56
Merck & Co., Inc. 57
Merrimack Pharmaceuticals, Inc. 58
NanoCarrier Co., Ltd. 59
NantKwest, Inc. 60
Natco Pharma Limited 61
NewLink Genetics Corporation 62
Novartis AG 63
Oncolytics Biotech Inc. 64
Oncovir, Inc. 65
Oryx GmbH & Co. KG 66
Pfizer Inc. 67
Pharmacyclics, Inc. 68
Phoenix Biotechnology, Inc. 69
Precision Biologics, Inc. 70
Rexahn Pharmaceuticals, Inc. 71
Silence Therapeutics Plc 72
Targovax ASA 73
Tiltan Pharma Ltd. 74
Tocagen Inc. 75
Zeria Pharmaceutical Co., Ltd. 76
Metastatic Pancreatic Cancer - Therapeutics Assessment 77
Assessment by Monotherapy Products 77
Assessment by Combination Products 78
Assessment by Target 79
Assessment by Mechanism of Action 85
Assessment by Route of Administration 91
Assessment by Molecule Type 93
Drug Profiles 95
(curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile 95
5B1-ADC - Drug Profile 96
acalabrutinib - Drug Profile 97
aldoxorubicin hydrochloride - Drug Profile 100
alpelisib - Drug Profile 114
ARQ-761 - Drug Profile 117
asparaginase - Drug Profile 118
atezolizumab - Drug Profile 125
Atu-027 - Drug Profile 138
avasimibe - Drug Profile 142
AXP-10711 - Drug Profile 143
BI-853520 - Drug Profile 145
binimetinib - Drug Profile 146
BL-8040 - Drug Profile 153
BNC-101 - Drug Profile 163
Cellular Immunotherapy for Oncology - Drug Profile 166
Cellular Immunotherapy for Oncology - Drug Profile 167
Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile 168
ceritinib - Drug Profile 170
CG-200745 - Drug Profile 175
Charis-1000 - Drug Profile 176
CIM-1 - Drug Profile 177
cisplatin - Drug Profile 178
CPI-613 - Drug Profile 180
dacomitinib - Drug Profile 185
ensituximab - Drug Profile 188
FB-704A - Drug Profile 192
flucytosine ER + vocimagene amiretrorepvec - Drug Profile 193
galunisertib - Drug Profile 200
glufosfamide - Drug Profile 203
GS-5745 - Drug Profile 205
GSK-2256098 - Drug Profile 207
haNK Program - Drug Profile 209
HuMab-5B1 - Drug Profile 210
ibrutinib - Drug Profile 213
IMM-101 - Drug Profile 238
INCB-52793 - Drug Profile 240
indoximod - Drug Profile 241
irinotecan hydrochloride - Drug Profile 246
istiratumab - Drug Profile 257
lapatinib ditosylate - Drug Profile 259
LCL-161 - Drug Profile 264
MesoCART - Drug Profile 266
MK-2206 - Drug Profile 267
MK-2206 + selumetinib sulfate - Drug Profile 270
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 271
MVT-1075 - Drug Profile 273
napabucasin - Drug Profile 274
nimotuzumab - Drug Profile 280
NRCAN-019 - Drug Profile 284
olaparib - Drug Profile 286
paclitaxel albumin bound - Drug Profile 295
palbociclib - Drug Profile 303
Parvoryx - Drug Profile 313
PBI-05204 - Drug Profile 315
PCI-27483 - Drug Profile 317
pelareorep - Drug Profile 319
PLX-7486 - Drug Profile 333
Poly-ICLC - Drug Profile 334
PRI-724 - Drug Profile 337
RG-7876 - Drug Profile 339
ribociclib succinate - Drug Profile 340
rottlerin - Drug Profile 344
rucaparib camsylate - Drug Profile 345
RX-0201 - Drug Profile 352
SGT-53 - Drug Profile 356
Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer - Drug Profile 358
sonidegib phosphate - Drug Profile 359
TG-01 - Drug Profile 363
TL-118 - Drug Profile 365
tosedostat - Drug Profile 367
trametinib dimethyl sulfoxide - Drug Profile 372
ubidecarenone - Drug Profile 376
ulixertinib - Drug Profile 378
ulocuplumab - Drug Profile 379
Vaccine for Oncology - Drug Profile 381
veliparib - Drug Profile 382
Z-360 - Drug Profile 388
Metastatic Pancreatic Cancer - Dormant Projects 389
Metastatic Pancreatic Cancer - Discontinued Products 394
Metastatic Pancreatic Cancer - Product Development Milestones 397
Featured News & Press Releases 397
Appendix 409
Methodology 409
Coverage 409
Secondary Research 409
Primary Research 409
Expert Panel Validation 409
Contact Us 409
Disclaimer 410

List of Tables

Number of Products under Development for Metastatic Pancreatic Cancer, H2 2016 17
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H2 2016 18
Number of Products under Development by Companies, H2 2016 19
Number of Products under Development by Companies, H2 2016 (Contd..1) 20
Number of Products under Development by Companies, H2 2016 (Contd..2) 21
Number of Products under Development by Companies, H2 2016 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H2 2016 23
Comparative Analysis by Late Stage Development, H2 2016 24
Comparative Analysis by Clinical Stage Development, H2 2016 25
Comparative Analysis by Early Stage Development, H2 2016 26
Products under Development by Companies, H2 2016 27
Products under Development by Companies, H2 2016 (Contd..1) 28
Products under Development by Companies, H2 2016 (Contd..2) 29
Products under Development by Companies, H2 2016 (Contd..3) 30
Products under Development by Companies, H2 2016 (Contd..4) 31
Products under Investigation by Universities/Institutes, H2 2016 32
Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2016 33
Metastatic Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H2 2016 34
Metastatic Pancreatic Cancer - Pipeline by ArQule, Inc., H2 2016 35
Metastatic Pancreatic Cancer - Pipeline by Array BioPharma Inc., H2 2016 36
Metastatic Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2016 37
Metastatic Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2016 38
Metastatic Pancreatic Cancer - Pipeline by Berg LLC, H2 2016 39
Metastatic Pancreatic Cancer - Pipeline by BioLineRx, Ltd., H2 2016 40
Metastatic Pancreatic Cancer - Pipeline by Bionomics Limited, H2 2016 41
Metastatic Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 42
Metastatic Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H2 2016 43
Metastatic Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 44
Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H2 2016 45
Metastatic Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H2 2016 46
Metastatic Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016 47
Metastatic Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H2 2016 48
Metastatic Pancreatic Cancer - Pipeline by CTI BioPharma Corp., H2 2016 49
Metastatic Pancreatic Cancer - Pipeline by CytRx Corporation, H2 2016 50
Metastatic Pancreatic Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 51
Metastatic Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2016 52
Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H2 2016 53
Metastatic Pancreatic Cancer - Pipeline by Ensol Biosciences Inc., H2 2016 54
Metastatic Pancreatic Cancer - Pipeline by Erytech Pharma SA, H2 2016 55
Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 56
Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H2 2016 57
Metastatic Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H2 2016 58
Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 59
Metastatic Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2016 60
Metastatic Pancreatic Cancer - Pipeline by Incyte Corporation, H2 2016 61
Metastatic Pancreatic Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016 62
Metastatic Pancreatic Cancer - Pipeline by Merck & Co., Inc., H2 2016 63
Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 64
Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016 65
Metastatic Pancreatic Cancer - Pipeline by NantKwest, Inc., H2 2016 66
Metastatic Pancreatic Cancer - Pipeline by Natco Pharma Limited, H2 2016 67
Metastatic Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H2 2016 68
Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H2 2016 69
Metastatic Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016 70
Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H2 2016 71
Metastatic Pancreatic Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016 72
Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H2 2016 73
Metastatic Pancreatic Cancer - Pipeline by Pharmacyclics, Inc., H2 2016 74
Metastatic Pancreatic Cancer - Pipeline by Phoenix Biotechnology, Inc., H2 2016 75
Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H2 2016 76
Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 77
Metastatic Pancreatic Cancer - Pipeline by Silence Therapeutics Plc, H2 2016 78
Metastatic Pancreatic Cancer - Pipeline by Targovax ASA, H2 2016 79
Metastatic Pancreatic Cancer - Pipeline by Tiltan Pharma Ltd., H2 2016 80
Metastatic Pancreatic Cancer - Pipeline by Tocagen Inc., H2 2016 81
Metastatic Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co., Ltd., H2 2016 82
Assessment by Monotherapy Products, H2 2016 83
Assessment by Combination Products, H2 2016 84
Number of Products by Stage and Target, H2 2016 86
Number of Products by Stage and Mechanism of Action, H2 2016 92
Number of Products by Stage and Route of Administration, H2 2016 98
Number of Products by Stage and Molecule Type, H2 2016 100
Metastatic Pancreatic Cancer - Dormant Projects, H2 2016 395
Metastatic Pancreatic Cancer - Dormant Projects (Contd..1), H2 2016 396
Metastatic Pancreatic Cancer - Dormant Projects (Contd..2), H2 2016 397
Metastatic Pancreatic Cancer - Dormant Projects (Contd..3), H2 2016 398
Metastatic Pancreatic Cancer - Dormant Projects (Contd..4), H2 2016 399
Metastatic Pancreatic Cancer - Discontinued Products, H2 2016 400
Metastatic Pancreatic Cancer - Discontinued Products (Contd..1), H2 2016 401
Metastatic Pancreatic Cancer - Discontinued Products (Contd..2), H2 2016 402